The Omicron coronavirus variant detected in southern Africa could be the most likely candidate to displace the highly contagious Delta variant, the director of South Africa’s communicable disease institute said on November 30.
If you are not happy with the results below please do another search
50 search results for:
A panel of expert advisers to the U.S. Food and Drug Administration on November 30 narrowly voted to recommend the regulatory agency authorize Merck & Co.’s antiviral pill to treat Covid-19.
Deciphera Pharmaceuticals announced a restructuring with the intention of prioritizing clinical development of specific programs and streamlining the Waltham, Mass.-based company’s commercial operations. In addition to cutting one of its programs, Deciphera plans to reduce about 140 positions.
The head of the World Health Organization (WHO) voiced concern on November 30 that some countries were introducing blanket measures against the Omicron coronavirus variant that may not be necessary and penalized African nations unfairly.
White House Press Secretary Jen Psaki said on November 30 the Biden administration is continuing to work on building a consensus toward waving intellectual property rights tied to Covid-19 vaccines.
BioNTech and Pfizer’s COVID-19 vaccine will likely offer strong protection against any severe disease from the new Omicron virus variant, BioNTech’s Chief Executive told Reuters, as the firm weighs the need to upgrade its commonly used shot.
The U.S. Food and Drug Administration said on November 30 the regulatory agency was evaluating the effectiveness of authorized Covid-19 vaccines against the Omicron coronavirus variant and expects to have more information in the next few weeks.
One day after Bay Area-based Olema Pharmaceuticals announced that falsified information regarding its Phase I/II breast cancer data was circulating across the Internet, the company released topline data for OP-1250, a potential best-in-class complete estrogen receptor antagonist (CERAN).
The Centers for Disease Control and Prevention (CDC) shifted its recommendation on adults getting a booster Covid-19 vaccine to now include everyone ages 18 years and older as the threat of the new Omicron variant looms.
Merck & Co. Inc.’s experimental Covid-19 drug molnupiravir should have similar activity against any new coronavirus variant, a company executive said on NOvember 30.